Seagen, a wholly owned subsidiary of Pfizer is the lead sponsor of 16 current clinical trials in our USA, UK, China and Ireland registers. 5 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are Pembrolizumab, Tucatinib and Disitamab Vedotin. The most-studied condition is Carcinoma, Non-Small-Cell Lung.
| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651 · ClinicalTrials.gov ↗ · Colorectal Neoplasms
|
Phase 3 | Recruiting | 2022-10 | Ireland, UK, USA, China |
|
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
NCT06131840 · ClinicalTrials.gov ↗ · Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms
|
Phase 1 | Recruiting | 2023-11 | UK, USA, China |
|
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
NCT04389632 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms
|
Phase 1 | Recruiting | 2020-06 | UK, USA |
|
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT05208762 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma
Drugs: Pembrolizumab, PF-08046054 |
Phase 1 | Recruiting | 2022-10 | UK, USA, China |
|
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
NCT04879329 · ClinicalTrials.gov ↗ · Urothelial Carcinoma
Drugs: Disitamab Vedotin, Pembrolizumab |
Phase 2 | Recruiting | 2022-05 | UK, USA |
|
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
NCT05911295 · ClinicalTrials.gov ↗ · Urothelial Carcinoma
|
Phase 3 | Active, closed | 2023-09 | Ireland, UK, USA, China |
|
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors
NCT03485209 · ClinicalTrials.gov ↗ · Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer
|
Phase 2 | Active, closed | 2018-06 | UK, USA |
|
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
NCT06012435 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung
Drugs: Docetaxel, Sigvotatug vedotin |
Phase 3 | Active, closed | 2024-02 | UK, USA, China |
|
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
NCT03975647 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer
Drugs: Trastuzumab emtansine, Tucatinib |
Phase 3 | Active, closed | 2019-10 | UK, USA, China |
|
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
NCT05132582 · ClinicalTrials.gov ↗ · HER2 Positive Breast Cancer
|
Phase 3 | Active, closed | 2022-03 | UK, USA, China |
|
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
NCT04579380 · ClinicalTrials.gov ↗ · Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms
|
Phase 2 | Active, closed | 2021-01 | UK, USA |
|
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
NCT04404283 · ClinicalTrials.gov ↗ · Diffuse Large B-cell Lymphoma
|
Phase 3 | Active, closed | 2020-08 | UK, USA |
|
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
NCT04227847 · ClinicalTrials.gov ↗ · Myelodysplastic Syndrome, Acute Myeloid Leukemia
Drugs: Azacitidine, Venetoclax |
Phase 1 | Active, closed | 2020-08 | USA |
|
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892 · ClinicalTrials.gov ↗ · Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms
Drugs: Disitamab Vedotin, Tucatinib |
Phase 2 | Active, closed | 2024-05 | UK, USA |
|
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
NCT06003231 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms
Drug: Disitamab Vedotin |
Phase 2 | Active, closed | 2023-11 | UK, USA |
|
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
NCT04430738 · ClinicalTrials.gov ↗ · Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma
|
Phase 2 | Active, closed | 2020-09 | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 16 | 5 |
| Clinical trials in UK | 14 | 5 |
| Clinical trials in China | 7 | 3 |
| Clinical trials in Ireland | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
| Sponsor | Trials |
|---|---|
| Janssen Research & Development | 12 |
| US Oncology Research | 2 |
| Mirati Therapeutics | 1 |
| Johnson & Johnson Enterprise Innovation | 1 |
| Bio-Thera Solutions | 1 |
Sponsors with the most current trials registered for this condition.
Seagen, a wholly owned subsidiary of Pfizer is the lead sponsor of 16 current trials on ClinicalTrials.gov in our USA, UK, China and Ireland registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 5 of its 16 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Its current trials name 28 drugs and biologicals as interventions. The most frequent are Pembrolizumab (6), Tucatinib (6), Disitamab Vedotin (4), Trastuzumab (4) and Carboplatin (3). The number in brackets is how many of its trials name each drug.
Yes. 2 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.